Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma
| العنوان: | Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma |
|---|---|
| المؤلفون: | Mangin, Marie‐Alix, Boespflug, Amélie, Maucort Boulch, Delphine, Vacheron, Charles‐Hervé, Carpentier, Isabelle, Thomas, Luc, Dalle, Stéphane |
| المصدر: | Cancer Medicine, Vol 10, Iss 10, Pp 3155-3164 (2021) Cancer Medicine |
| بيانات النشر: | Wiley, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Male, nivolumab, Clinical Cancer Research, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, targeted therapy, Progression-Free Survival, cytotoxic chemotherapy, Antineoplastic Combined Chemotherapy Protocols, melanoma, Humans, Female, immunotherapy, pembrolizumab, Immune Checkpoint Inhibitors, Protein Kinase Inhibitors, RC254-282, Original Research, Aged, Retrospective Studies |
| الوصف: | Background Cytotoxic chemotherapy (CC) is currently used in metastatic melanoma after patients have developed resistance to immune checkpoint inhibitors (ICI) and/or Mitogen‐Activated Protein Kinase inhibitors (MAPKi). We sought to evaluate if a previous treatment by ICI or MAPKi influences clinical outcomes in patients treated by CC in metastatic melanoma. Methods Eighty‐eight patients with a metastatic melanoma, treated by CC after a previous treatment by ICI or MAPKi between January 2009 and October 2019, were retrospectively analyzed. Progression‐Free‐Survival (PFS), Overall Survival (OS), Overall Response Rate (ORR), and Disease Control Rate (DCR) were evaluated in patients treated by CC according to their prior treatment by ICI or MAPKi. Results Patients treated by CC after ICI tended to have a better median PFS (2.81 months (2.39–5.30) versus 2.40 months (0.91–2.75), p = 0.023), median OS (6.03 months (3.54–11.54) versus 4.44 months (1.54–8.59), p = 0.27), DCR (26.0% vs. 10.5%, p = 0.121) and ORR (22.0% vs. 7.9% p = 0.134) than those previously treated by MAPKi. Conclusions A prior treatment by an MAPKi may be associated with a worse response to CC than ICI, and further investigations should be performed to confirm if there is a clinical benefit to propose CC in this setting. Cytotoxic chemotherapy may be used as a last resort after failure of a prior treatment by targeted therapy or immunotherapy in metastatic melanoma. The aim of this study was to evaluate if a prior treatment by targeted therapy or immunotherapy may influence clinical outcomes in patients treated by a second line cytotoxic chemotherapy in metastatic melanoma. We found that patients treated by cytotoxic chemotherapy after prior treatment by targeted therapy, tended to have worse clinical outcomes than patients previously treated by immunotherapy and that prior immunotherapy does not seem to potentiate response to cytotoxic chemotherapy when compared to historical cohorts. |
| اللغة: | English |
| تدمد: | 2045-7634 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::5e4b7b286b5b8ea479c3cc8412c00cfdTest https://doaj.org/article/0ab964971a5348f598cbc837ed78ca3dTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.pmid.dedup....5e4b7b286b5b8ea479c3cc8412c00cfd |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20457634 |
|---|